2025
Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study. Journal Of Clinical Oncology 2025, 43: 275-275. DOI: 10.1200/jco.2025.43.4_suppl.275.Peer-Reviewed Original ResearchMolecular residual diseaseColorectal cancerCtDNA detectionDetection of molecular residual diseaseWeek 8Week 4Resectable colorectal cancerYear of surgeryTime of surgerySingle nucleotide variantsYear Follow-UpPost-surgical timesNeoadjuvant therapyResidual diseaseCurative intentMRD assaysResidual cancerClinical relapseDisease recurrenceCtDNA concentrationRecurrent cancerClinical outcomesCfDNA concentrationFollow-upRecurrence
2024
Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort
Laakso S, Oh J, Raufdeen F, Jones A, Reiskanen H, Feb K, Levit E, Solomon A. Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort. Multiple Sclerosis Journal 2024, 31: 607-611. PMID: 39727322, DOI: 10.1177/13524585241309257.Peer-Reviewed Original ResearchTrigeminal neuralgiaClinical relapseMultiple sclerosisActive diseaseEvidence of active diseaseDisease course of MSAssociated with multiple sclerosisCourse of MSDemyelination symptomsMulticenter cohortDisease courseTherapeutic decisionsTherapeutic implicationsMS diagnosisNeuralgiaRelapseDiseaseOnsetSclerosisQuantitative susceptibility mapping is more sensitive and specific than phase imaging in detecting chronic active multiple sclerosis lesion rims: pathological validation
Gillen K, Nguyen T, Dimov A, Kovanlikaya I, Luu H, Demmon E, Markowitz D, Bagnato F, Pitt D, Gauthier S, Wang Y. Quantitative susceptibility mapping is more sensitive and specific than phase imaging in detecting chronic active multiple sclerosis lesion rims: pathological validation. Brain Communications 2024, 7: fcaf011. PMID: 39916751, PMCID: PMC11800486, DOI: 10.1093/braincomms/fcaf011.Peer-Reviewed Original ResearchPhase imagesQuantitative susceptibility mappingPerls' stainPredictive valueLesion rimFrequency of clinical relapsesNegative predictive valuePositive predictive valuePathological validationDecreased brain volumeProgression to disabilityQuantitative susceptibility mapping imagesClinical relapseBrain volumeMicroglial markersGold standardLesionsMultiple sclerosis lesionsParamagnetic rimMap imagesMeningeal lymphatic function promotes oligodendrocyte survival and brain myelination
das Neves S, Delivanoglou N, Ren Y, Cucuzza C, Makuch M, Almeida F, Sanchez G, Barber M, Rego S, Schrader R, Faroqi A, Thomas J, McLean P, Oliveira T, Irani S, Piehl F, Da Mesquita S. Meningeal lymphatic function promotes oligodendrocyte survival and brain myelination. Immunity 2024, 57: 2328-2343.e8. PMID: 39217987, PMCID: PMC11464205, DOI: 10.1016/j.immuni.2024.08.004.Peer-Reviewed Original ResearchLymphatic functionMeningeal lymphatic dysfunctionLymphatic dysfunctionVascular endothelial growth factor-CState of immunosuppressionMyeloid cell activationHuman demyelinating diseasesBrain myelinMature oligodendrocyte numbersClinical relapseImmunocompetent miceAdult miceMeningeal lymphatic functionAxonal lossOligodendrocyte survivalDemyelinating diseaseOligodendrocyte numbersVessel ablationAdaptive immunityCell activationCerebrospinal fluidGene expression changesMature oligodendrocytesOligodendrocyte functionGlial cellsUltra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
Garcia-Murillas I, Cutts R, Abbott C, Boyle S, Pugh J, Chen R, Dunne K, Bunce C, Johnston S, Ring A, Russell S, Evans A, Skene A, Wheatley D, Smith I, Turner N. Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer. Journal Of Clinical Oncology 2024, 42: 1010-1010. DOI: 10.1200/jco.2024.42.16_suppl.1010.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNAEarly breast cancerBreast cancer patientsFollow-upNeoadjuvant chemotherapyResidual diseaseClinical relapseCtDNA detectionClinical outcomesBreast cancerAssociated with relapse free survivalDetection of molecular residual diseaseCancer patientsCirculating tumor DNA levelsLevels of circulating tumor DNAHigh risk of relapseHigh riskCirculating tumor DNA detectionMedian lead-timeRelapse free survivalDe-escalation studiesBreast cancer relapseShortened overall survivalBaseline prior to treatment
2023
Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
Anderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R, Ciplea A, Cooper J, Fabian M, Hale T, Jacobs D, Kakara M, Krysko K, Longbrake E, Marcus J, Repovic P, Riley C, Romeo A, Rutatangwa A, West T, Hellwig K, LaHue S, Bove R. Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Annals Of Clinical And Translational Neurology 2023, 10: 2053-2064. PMID: 37675826, PMCID: PMC10647007, DOI: 10.1002/acn3.51893.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderDisease-modifying therapiesMultiple sclerosisAnti-CD20 monoclonal antibody therapyCD20 IgG1 monoclonal antibodyInfant development outcomesPatient questionnaire responsesRelative infant doseOptica spectrum disorderMonoclonal antibody therapyIgG1 monoclonal antibodyMature breastmilkClinical relapseDisease activityInfant doseMAb therapyInfant outcomesAntibody therapyPostpartum womenPostpartum periodMedical recordsInfant growthPostpartum treatmentNeurological conditionsBreastmilkTracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Abbosh C, Frankell A, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa T, Weiss J, Schroeder M, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black J, Martínez-Ruiz C, Bakir M, Pich O, Watkins T, Lim E, Huebner A, Moore D, Godin-Heymann N, L’Hernault A, Bye H, Odell A, Kalavakur P, Gomes F, Patel A, Manzano E, Hiley C, Carey N, Riley J, Cook D, Hodgson D, Stetson D, Barrett J, Kortlever R, Evan G, Hackshaw A, Daber R, Shaw J, Aerts H, Licon A, Stahl J, Jamal-Hanjani M, Birkbak N, McGranahan N, Swanton C. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 2023, 616: 553-562. PMID: 37055640, PMCID: PMC7614605, DOI: 10.1038/s41586-023-05776-4.Peer-Reviewed Original ResearchConceptsCirculating tumor DNANon-small-cell lung cancerMetastatic disseminationClinical outcomesPlasma samplesEarly-stage non-small-cell lung cancerCirculating tumor DNA levelsCirculating tumor DNA detectionCytotoxic adjuvant therapyPreoperative ctDNA detectionResidual tumor cellsLongitudinal plasma samplesCancer cell fractionBiomarker of relapseProcess of metastatic disseminationAnalysis of plasma samplesClinical relapseDisease relapseAdjuvant therapyTumor DNAPreoperative plasmaRadiological surveillanceCtDNA detectionPatient cohortTumor cellsPredictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Singh S, Jangi S. Predictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission. Journal Of Clinical Gastroenterology 2023, 58: 195-199. PMID: 36753459, PMCID: PMC10406966, DOI: 10.1097/mcg.0000000000001834.Peer-Reviewed Original ResearchConceptsEtiology of relapseRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionDiscontinuation of therapyClinical relapseUlcerative colitisNormalization of C-reactive proteinCumulative riskRetrospective cohort studyC-reactive proteinTufts Medical CenterEndoscopic remissionHistological remissionRelapse riskIdentified etiologyRemissionRelapseCohort studyPatientsHistological changesMedical recordsColitisElectronic medical records
2022
Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy
Fichtner ML, Hoehn KB, Ford EE, Mane-Damas M, Oh S, Waters P, Payne AS, Smith ML, Watson CT, Losen M, Martinez-Martinez P, Nowak RJ, Kleinstein SH, O’Connor K. Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy. Acta Neuropathologica Communications 2022, 10: 154. PMID: 36307868, PMCID: PMC9617453, DOI: 10.1186/s40478-022-01454-0.Peer-Reviewed Original ResearchConceptsB cell depletion therapyB cell clonesMuSK-MG patientsMyasthenia gravisB cellsMG patientsDepletion therapyCell clonesAutoantibody-producing B cellsMuscle-specific tyrosine kinaseComplete stable remissionB cell receptor repertoireCell receptor repertoireValuable candidate biomarkersB cell receptorMG relapseClinical relapseStable remissionDisease relapseAutoimmune disordersRelapsePatientsAcetylcholine receptorsCandidate biomarkersReceptor repertoirePREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Jangi S. PREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION. Inflammatory Bowel Diseases 2022, 28: s47-s48. DOI: 10.1093/ibd/izac015.073.Peer-Reviewed Original ResearchRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionHistological remissionClinical relapseUlcerative colitisDisease durationEndoscopic remissionCumulative riskMedian follow-up timeDuration of follow-upPredictive of clinical relapseMedian disease durationFollow-up timeRetrospective cohort studyPredictors of relapseMayo endoscopic scoreTufts Medical CenterPatient-reported outcomesMedian ageRelapse rateRelapse riskEndoscopic scoreElectronic medical records
2020
IgG Index Revisited: Diagnostic Utility and Prognostic Value in Multiple Sclerosis
Zheng Y, Cai M, Yang F, Zhou J, Fang W, Shen C, Zhang Y, Ding M. IgG Index Revisited: Diagnostic Utility and Prognostic Value in Multiple Sclerosis. Frontiers In Immunology 2020, 11: 1799. PMID: 32973754, PMCID: PMC7468492, DOI: 10.3389/fimmu.2020.01799.Peer-Reviewed Original ResearchConceptsCohort of clinically isolated syndromeOligoclonal band positivityOligoclonal band statusOligoclonal bandsIgG indexPrognostic valueDiagnostic utilityMultiple sclerosisExpanded Disability Status Scale worseningAccurate diagnosis of multiple sclerosisMS diagnosisAttack of MSNegative oligoclonal bandsAsian populationsClinically isolated syndromeDiagnosis of multiple sclerosisElevated IgG indexEarly disease activityClinical relapseRetrospective studyDisease activityClinical challengeMS patientsAccurate diagnosisPredictive valueThe B cell immunobiology that underlies CNS autoantibody-mediated diseases
Sun B, Ramberger M, O’Connor K, Bashford-Rogers RJM, Irani SR. The B cell immunobiology that underlies CNS autoantibody-mediated diseases. Nature Reviews Neurology 2020, 16: 481-492. PMID: 32724223, PMCID: PMC9364389, DOI: 10.1038/s41582-020-0381-z.Peer-Reviewed Original ResearchConceptsAutoantigen-specific B cellsB cellsPathogenic autoantibodiesB cell tolerance checkpointsAutoantibody-mediated diseasesB cell immunobiologyLong-term morbidityHigher serum levelsCirculation of patientsSource of autoantibodiesSite of pathologyB-cell lineageClinical relapseAvailable medicationsSerum levelsIntrathecal synthesisCNS diseaseTolerance checkpointsPlasma cellsTherapeutic effectCerebrospinal fluidGerminal centersAutoantibodiesDiseasePatients
2019
Treatment Strategies and Outcome of Parvovirus B19 Infection in Kidney Transplant Recipients: A Case Series and Literature Review of 128 patients
Rosado-Canto R, Carrillo-Pérez D, Jiménez J, Cuellar-Rodríguez J, Parra-Avila I, Alberú J, Morales-Buenrostro L. Treatment Strategies and Outcome of Parvovirus B19 Infection in Kidney Transplant Recipients: A Case Series and Literature Review of 128 patients. Revista De Investigación Clínica 2019, 71: 265-274. PMID: 31448778, DOI: 10.24875/ric.19002921.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsIntravenous immunoglobulinPVB19 infectionTransplant recipientsReduction of immunosuppressionSevere aregenerative anemiaMedical literatureParvovirus B19 infectionAnemia improvementImmunosuppressive regimenClinical relapseReduced immunosuppressionDecreased immunosuppressionB19 infectionConservative therapyRetrospective reviewStandard doseAregenerative anemiaMedian timeCase seriesParvovirus B19Antiviral treatmentFollow-upTreatment strategiesAcademic medical center
2016
Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis
Park S, Abdi T, Gentry M, Laine L. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. The American Journal Of Gastroenterology 2016, 111: 1692. PMID: 27725645, DOI: 10.1038/ajg.2016.418.Peer-Reviewed Original ResearchConceptsRelapse/exacerbationHistological remissionEndoscopic remissionClinical remissionHistological activityClinical outcomesUlcerative colitisHistological statusClinical relapseHistological featuresLamina propriaChronic inflammatory cell infiltrateAdditional prognostic utilityHistological disease activityProportion of patientsInflammatory bowel diseaseInflammatory cell infiltrateLack of blindingImproved clinical outcomesDifferent histological featuresSpecific histological featuresRandom-effects modelFixed-effects modelDisease activityUC patientsThe Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample
Oedegaard K, Alda M, Anand A, Andreassen O, Balaraman Y, Berrettini W, Bhattacharjee A, Brennand K, Burdick K, Calabrese J, Calkin C, Claasen A, Coryell W, Craig D, DeModena A, Frye M, Gage F, Gao K, Garnham J, Gershon E, Jakobsen P, Leckband S, McCarthy M, McInnis M, Maihofer A, Mertens J, Morken G, Nievergelt C, Nurnberger J, Pham S, Schoeyen H, Shekhtman T, Shilling P, Szelinger S, Tarwater B, Yao J, Zandi P, Kelsoe J. The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample. BMC Psychiatry 2016, 16: 129. PMID: 27150464, PMCID: PMC4857276, DOI: 10.1186/s12888-016-0732-x.Peer-Reviewed Original ResearchConceptsLithium monotherapyBipolar disorderLithium responseMechanism of actionClinical managementValproic acidLithium respondersSingle nucleotide polymorphismsMethods/designThis studyCox proportional hazards modelProspective study sampleLarge prospective cohortLarge prospective studiesClinical Global ImpressionInitiation of treatmentMood-stabilizing medicationsBipolar Disorder (STEP-BD) studyProportional hazards modelResults of treatmentCommon psychiatric disordersMEq/L.Genome-wide association studiesClinical relapseProspective cohortRemitting course
2015
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
Sausen M, Phallen J, Adleff V, Jones S, Leary R, Barrett M, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban C, Scharpf R, White J, O’Dwyer P, Allen P, Eshleman J, Thompson C, Klimstra D, Linehan D, Maitra A, Hruban R, Diaz L, Von Hoff D, Johansen J, Drebin J, Velculescu V. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications 2015, 6: 7686. PMID: 26154128, PMCID: PMC4634573, DOI: 10.1038/ncomms8686.Peer-Reviewed Original ResearchConceptsGenomic alterationsGenetic predictors of outcomeDetect circulating tumor DNAAssociated with improved survivalTumor-specific mutationsPancreatic cancer patientsLiquid biopsy analysisClinical implicationsPredictors of outcomeWhole-exome analysisDetection of ctDNAPotential therapeutic utilityClinical relapseLocalized diseaseTumor DNAPancreatic adenocarcinomaImproved survivalPancreatic cancerSolid cancersTumor typesBiopsy analysisPoor outcomeCancer patientsSomatic mutationsTumorAdvancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia
Hokland P, Ommen H, Mulé M, Hourigan C. Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. Seminars In Hematology 2015, 52: 184-192. PMID: 26111465, PMCID: PMC4484880, DOI: 10.1053/j.seminhematol.2015.04.001.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid leukemiaNon-acute promyelocytic leukemiaAcute myeloid leukemia patientsResidual disease burdenResponse to treatmentPersonalized treatment plansMRD measurementsClinical relapseClinical decision-makingPreclinical validationNon-APLTreatment planningPromyelocytic leukemiaLeukemiaMRDCurrent patient statusPatientsDisease burdenLaboratory investigationsPatient statusNatural hesitancyAssay sensitivityDrug developmentSensitive tool
2011
Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis
Vélez de Mendizábal N, Carneiro J, Solé R, Goñi J, Bragard J, Martinez-Forero I, Martinez-Pasamar S, Sepulcre J, Torrealdea J, Bagnato F, Garcia-Ojalvo J, Villoslada P. Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis. BMC Systems Biology 2011, 5: 114. PMID: 21762505, PMCID: PMC3155504, DOI: 10.1186/1752-0509-5-114.Peer-Reviewed Original ResearchConceptsCross-regulationT cellsAutoimmune diseasesImmune systemMultiple sclerosisEffector T cellsRegulatory T cellsT cell memoryTissue damageEffects of such therapyPathogenesis of autoimmune diseasesT cell activationPredicting disease courseModulating effectorsBiological knowledgeMolecular mechanismsIrreversible tissue damageClinical relapseStochastic eventsRegulatory populationsCentral toleranceAutoimmune activityDisease courseNegative feedbackEffector
2000
Lymphotoxin in inflammation and lymphoid organ development: Variations on a theme
Ruddle N. Lymphotoxin in inflammation and lymphoid organ development: Variations on a theme. Progress In Inflammation Research 2000, 83-88. DOI: 10.1007/978-3-0348-8468-6_8.Peer-Reviewed Original ResearchAutoimmune diseasesLymphoid organsLymphoid organ developmentT cellsTarget organsAntigen-specific T cellsAdditional T cellsLocal lymphoid organsTertiary lymphoid organsConsequence of inflammationLymphoid neogenesisClinical relapseAutoimmune inflammationLocal target organLymphoid tissueInflammatory reactionB cellsInflammationTransgenic miceTissue damageDiseaseTNF familyOrgansUnrelated moleculesOrgan development
1993
Short‐term response to dietary therapy in molybdenum cofactor deficiency
Boles R, Ment L, Meyn M, Horwich A, Kratz L, Rinaldo P. Short‐term response to dietary therapy in molybdenum cofactor deficiency. Annals Of Neurology 1993, 34: 742-744. PMID: 7694543, DOI: 10.1002/ana.410340520.Peer-Reviewed Original ResearchConceptsMolybdenum cofactor deficiencyCofactor deficiencyShort-term clinical improvementDietary methionine restrictionUrinary sulphiteClinical relapseClinical improvementLaboratory featuresDietary therapySevere irritabilityLactic acidosisHead growthMethionine restrictionDevelopmental delayCysteine supplementationCommercial dipstickTherapyIrritabilityDeficiencyDevelopmental progressRelapseHypouricemiaAcidosisInfantsMicrocephaly
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply